Porton Fine Chemicals vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Porton Fine Chemicals Ltd (300363.CS)

Q3 202614 Jul – 24 Aug 2026

▲3▼1

Porton swings to loss on Slovenia writedown, but core profit and CGT license advance

Slovenia project termination triggers 330 million yuan impairment and first-half loss Porton expects a first-half 2026 net loss of 210-250 million yuan, versus a profit last year, after scrapping its Slovenia R&D and production base and taking a roughly 330 million yuan writedown. The final interim report confirmed a 224 million yuan loss. This one-time hit is the main reason the stock looks weak on headline numbers.
The impairment is the single biggest swing factor behind the reported loss and the market's negative reaction.
Core profit surges 196-343% excluding impairment on higher revenue and margins Strip out the Slovenia writedown and Porton's underlying profit was 80-120 million yuan, up 196-343% from a year earlier. Revenue rose 8-12% to 1.75-1.82 billion yuan, and gross margin improved about 4 percentage points on higher-margin product deliveries. This shows the operating business is actually getting healthier.
It separates the one-time loss from the real operating performance, which is what long-term investors care about.
Suzhou subsidiary wins first drug manufacturing license for cell and gene therapy Porton's majority-owned Suzhou unit obtained a drug manufacturing license, allowing it to commercially make cell and gene therapy products for clients. This opens a new, higher-value contract manufacturing business and supports future revenue growth beyond its traditional small-molecule work.
It is a concrete regulatory milestone that expands Porton's addressable market into a fast-growing area.
CRO sector rally lifts peers and Porton shares WuXi AppTec's blowout first-half results and raised guidance sent CRO stocks soaring, with the sector index up nearly 8% and Porton hitting its daily limit. Strong demand for outsourced drug development is lifting the whole group, though global GLP-1 capacity expansion is raising competition.
Sector momentum is a major short-term price driver for Porton, even if it is not company-specific.

August 202614 Jul – 24 Aug 2026

▲3▼1

Porton swings to loss on Slovenia writedown, but core profit and CGT license advance

Slovenia project termination triggers 330 million yuan impairment and first-half loss Porton expects a first-half 2026 net loss of 210-250 million yuan, versus a profit last year, after scrapping its Slovenia R&D and production base and taking a roughly 330 million yuan writedown. The final interim report confirmed a 224 million yuan loss. This one-time hit is the main reason the stock looks weak on headline numbers.
The impairment is the single biggest swing factor behind the reported loss and the market's negative reaction.
Core profit surges 196-343% excluding impairment on higher revenue and margins Strip out the Slovenia writedown and Porton's underlying profit was 80-120 million yuan, up 196-343% from a year earlier. Revenue rose 8-12% to 1.75-1.82 billion yuan, and gross margin improved about 4 percentage points on higher-margin product deliveries. This shows the operating business is actually getting healthier.
It separates the one-time loss from the real operating performance, which is what long-term investors care about.
Suzhou subsidiary wins first drug manufacturing license for cell and gene therapy Porton's majority-owned Suzhou unit obtained a drug manufacturing license, allowing it to commercially make cell and gene therapy products for clients. This opens a new, higher-value contract manufacturing business and supports future revenue growth beyond its traditional small-molecule work.
It is a concrete regulatory milestone that expands Porton's addressable market into a fast-growing area.
CRO sector rally lifts peers and Porton shares WuXi AppTec's blowout first-half results and raised guidance sent CRO stocks soaring, with the sector index up nearly 8% and Porton hitting its daily limit. Strong demand for outsourced drug development is lifting the whole group, though global GLP-1 capacity expansion is raising competition.
Sector momentum is a major short-term price driver for Porton, even if it is not company-specific.

Latest14 Jul – 24 Aug 2026

▲3▼1

Porton swings to loss on Slovenia writedown, but core profit and CGT license advance

Slovenia project termination triggers 330 million yuan impairment and first-half loss Porton expects a first-half 2026 net loss of 210-250 million yuan, versus a profit last year, after scrapping its Slovenia R&D and production base and taking a roughly 330 million yuan writedown. The final interim report confirmed a 224 million yuan loss. This one-time hit is the main reason the stock looks weak on headline numbers.
The impairment is the single biggest swing factor behind the reported loss and the market's negative reaction.
Core profit surges 196-343% excluding impairment on higher revenue and margins Strip out the Slovenia writedown and Porton's underlying profit was 80-120 million yuan, up 196-343% from a year earlier. Revenue rose 8-12% to 1.75-1.82 billion yuan, and gross margin improved about 4 percentage points on higher-margin product deliveries. This shows the operating business is actually getting healthier.
It separates the one-time loss from the real operating performance, which is what long-term investors care about.
Suzhou subsidiary wins first drug manufacturing license for cell and gene therapy Porton's majority-owned Suzhou unit obtained a drug manufacturing license, allowing it to commercially make cell and gene therapy products for clients. This opens a new, higher-value contract manufacturing business and supports future revenue growth beyond its traditional small-molecule work.
It is a concrete regulatory milestone that expands Porton's addressable market into a fast-growing area.
CRO sector rally lifts peers and Porton shares WuXi AppTec's blowout first-half results and raised guidance sent CRO stocks soaring, with the sector index up nearly 8% and Porton hitting its daily limit. Strong demand for outsourced drug development is lifting the whole group, though global GLP-1 capacity expansion is raising competition.
Sector momentum is a major short-term price driver for Porton, even if it is not company-specific.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.